A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer

CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression

(2015) Avinash Kambadakone et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

(2015) Jill Gilbert et al.   ORAL ONCOLOGY

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments

(2014) Laura D. Locati et al.   CANCER

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses

(2014) E. E. W. Cohen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

(2014) Han Sang Kim et al.   CLINICAL CANCER RESEARCH

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

(2013) Thomas E Hutson et al.   LANCET ONCOLOGY

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma

(2013) Rekha Gyanchandani et al.   ORAL ONCOLOGY

Human Papillomavirus Infection and Prognostic Predictors in Patients with Oropharyngeal Squamous Cell Carcinoma

(2012) Hui Huang et al.   Asian Pacific Journal of Cancer Prevention

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

(2012) Q.-T. Le et al.   CLINICAL CANCER RESEARCH

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

(2011) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker

(2011) Vicky Goh et al.   RADIOLOGY

Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420

(2010) Stephen K. Williamson et al.   JOURNAL OF CLINICAL ONCOLOGY

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

(2009) Joan H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

The Interleukin-8 Pathway in Cancer

(2008) D. J.J. Waugh et al.   CLINICAL CANCER RESEARCH

Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial

(2008) C. Fakhry et al.   JNCI-Journal of the National Cancer Institute